Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Auriclosene - NovaBay Pharmaceuticals

Drug Profile

Auriclosene - NovaBay Pharmaceuticals

Alternative Names: AgaDerm; AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovaBay Pharmaceuticals
  • Developer Alcon; Galderma; NovaBay Pharmaceuticals
  • Class Alkanesulfonic acids; Anti-infectives; Antibacterials; Antifungals; Chloramines; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase II/III Impetigo
  • Phase II Catheter infections
  • No development reported Acne; Escherichia coli infections; Klebsiella infections; Onychomycosis; Staphylococcal infections
  • Discontinued Infectious conjunctivitis; Otorhinolaryngological infections

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for preclinical development in Escherichia-coli-infections in USA
  • 28 Feb 2019 No recent reports of development identified for preclinical development in Klebsiella-infections in USA
  • 28 Feb 2019 No recent reports of development identified for preclinical development in Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top